Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
Last trade$8.90
Day change-$0.10 (-1.11%)
Day range$8.55 – $9.36
Volume82,243
Market cap$100M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$99.8M
Price / earnings
—
Price / book
11.5×
Price / sales
0.95×
EV / sales
1.13×
EV / EBITDA
-8.42×
Profitability
Earnings per share
-$2.44
Return on assets
-28.82%
Return on equity
-312.14%
Dividend yield
0%
Liquidity and leverage
Debt / equity
5.43×
Current ratio
2.96×
Quick ratio
2.96×
Cash ratio
1.99×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$19.07M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BDSX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$24.04M
$26.86M
$25.56M
$28.76M
$21.77M
$20.02M
$17.96M
$20.43M
Cost of revenue
$4.66M
$4.82M
$4.21M
$4.88M
$4.11M
$4.03M
$3.7M
$4.34M
Gross profit
$19.38M
$22.04M
$21.35M
$23.88M
$17.66M
$15.99M
$14.26M
$16.09M
Selling, general and administrative
$22.5M
$24.28M
$24.26M
$22.97M
$21.71M
$22.41M
$20.45M
$20.22M
Research and development
$2.99M
$3.14M
$3.29M
$2.87M
$2.99M
$3.27M
$2.87M
$2.41M
Total operating expenses
$25.49M
$27.43M
$27.55M
$25.84M
$24.71M
$25.71M
$23.39M
$22.74M
Operating income
-$6.11M
-$5.39M
-$6.2M
-$1.97M
-$7.05M
-$9.72M
-$9.14M
-$6.65M
Interest expense
-$2M
-$1.98M
-$1.98M
-$2.06M
-$2.07M
-$1.9M
-$1.69M
-$1.75M
Income before taxes
-$8.03M
-$7.27M
-$7.79M
-$3.98M
-$8.72M
-$11.47M
-$11.1M
-$8.25M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$8.03M
-$7.27M
-$7.79M
-$3.98M
-$8.72M
-$11.47M
-$11.1M
-$8.25M
Net income attributable to common shareholders
-$8.03M
-$7.27M
-$7.79M
-$3.98M
-$8.72M
-$11.47M
-$11.1M
-$8.25M
EBITDA
-$4.71M
-$3.99M
-$4.8M
-$579K
-$5.64M
-$8.26M
-$7.62M
-$5.1M
Basic earnings per share
-$0.75
-$0.71
-$0.81
-$0.49
-$1.16
-$1.56
-$1.52
-$1.12
Diluted earnings per share
-$0.75
-$0.71
-$0.81
-$0.49
-$1.16
-$1.56
-$1.52
-$1.12
Recent news
Company coverage with links to the original publishers.
In a comparison of two oncology-focused healthcare companies, Champions Oncology (CSBR) is recommended as the better buy over Biodesix (BDSX). While BDSX has surged 156.7% over the past year, CSBR offers more attractive valuation metrics and better risk-reward positioning. CSBR benefits from strong demand for oncology research services, expanding data licensing opportunities, and radiopharmaceutical development initiatives. BDSX shows promise through lung diagnostic test adoption and operational improvements, but trades at a higher valuation with less upside potential.
Sera Prognostics reported a quarterly loss of $0.16 per share, missing consensus estimates of $0.14, with revenues of $0.04 million falling 47.5% short of expectations. The stock has declined 34.6% year-to-date versus the S&P 500's 10.6% gain. The company holds a Zacks Rank #3 (Hold) rating and is expected to perform in line with the market.
Biodesix, Inc. (Nasdaq: BDSX) announced that its leadership team will present at two upcoming investor conferences in November 2026. The company will participate in a fireside chat and 1x1 meetings at the UBS Global Healthcare Conference on November 10 in Palm Beach Gardens, FL, and 1x1 meetings at the Craig-Hallum Alpha Select Conference on November 17 in New York, NY. Presentations will be webcast live on the company's investor relations website.
Biodesix, Inc. (BDSX) has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting an upward trend in earnings estimates over the past three months with a 7.8% increase in consensus estimates. The upgrade positions the stock in the top 20% of Zacks-covered stocks, suggesting potential near-term price appreciation driven by improving business fundamentals and institutional investor buying pressure.
Biodesix announced a strategic partnership with Vanderbilt University to develop a radiomics-based test for lung nodule risk assessment that combines blood-based and imaging biomarkers using AI. The first product is expected to be commercially available in 2028, with initial data presented at RSNA in December 2026. This initiative expands Biodesix's lung diagnostics platform and positions the company to develop multimodal solutions across various pulmonary diseases.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.